Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Ustekinumab treatment didn't prevent frontal fibrosing alopecia.

JAK inhibitors are effective treatments for alopecia areata.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.

Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.

Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Switching Janus kinase inhibitors helped some patients with severe alopecia areata regrow hair, but insurance issues can worsen the condition.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

New treatments like JAK inhibitors offer hope for better alopecia areata management.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.

A woman lost vision in one eye after a forehead injection, but prompt treatment led to partial vision recovery.

Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

Ocrelizumab may cause delayed hair loss in some patients.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

AI-09 is safe, effective, and reduces wrinkles for up to 6 months.

Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.